Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
OPK 
Opko Health Inc (OPK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: OPK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $3.99
1 Year Target Price $3.99
| 2 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -41.37% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.05B USD | Price to earnings Ratio - | 1Y Target Price 3.99 |
Price to earnings Ratio - | 1Y Target Price 3.99 | ||
Volume (30-day avg) 7 | Beta 1.37 | 52 Weeks Range 1.19 - 2.04 | Updated Date 06/30/2025 |
52 Weeks Range 1.19 - 2.04 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -5.66% | Operating Margin (TTM) -44.79% |
Management Effectiveness
Return on Assets (TTM) -8.2% | Return on Equity (TTM) -3.04% |
Valuation
Trailing PE - | Forward PE 64.52 | Enterprise Value 1107684963 | Price to Sales(TTM) 1.52 |
Enterprise Value 1107684963 | Price to Sales(TTM) 1.52 | ||
Enterprise Value to Revenue 1.61 | Enterprise Value to EBITDA 7.36 | Shares Outstanding 793052992 | Shares Floating 375137767 |
Shares Outstanding 793052992 | Shares Floating 375137767 | ||
Percent Insiders 46.81 | Percent Institutions 31.12 |
Analyst Ratings
Rating 3 | Target Price 3.99 | Buy 4 | Strong Buy 2 |
Buy 4 | Strong Buy 2 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Opko Health Inc
Company Overview
History and Background
Opko Health Inc. was founded in 1991 (originally IVAX Corporation), focusing on pharmaceuticals. It evolved through acquisitions and strategic shifts, particularly under Dr. Phillip Frost, expanding into diagnostics and biopharmaceuticals.
Core Business Areas
- Pharmaceuticals: Opko develops, manufactures, and sells pharmaceutical products, including Rayaldee for secondary hyperparathyroidism in adults with chronic kidney disease and several other specialty drugs.
- Diagnostics: Opko operates a clinical laboratory business, BioReference Laboratories, providing diagnostic testing services.
- Biologics: Focus on developing novel therapies for various diseases, particularly in endocrinology, including hGH-CTP, a long-acting human growth hormone.
Leadership and Structure
Dr. Phillip Frost serves as Chairman and CEO. The company has a typical corporate structure with a board of directors and various executive management positions overseeing different business units.
Top Products and Market Share
Key Offerings
- Rayaldee: Rayaldee (calcifediol) is a treatment for secondary hyperparathyroidism in adults with chronic kidney disease. Market share information is not publicly and readily available, but competes with other vitamin D analogs and phosphate binders. Competitors include Amgen (Sensipar), Sanofi (Zaltrap).
- BioReference Laboratories: A clinical laboratory providing a wide range of diagnostic testing services. Specific market share data isn't readily available. Competitors include Quest Diagnostics (DGX), Laboratory Corporation of America (LH).
- hGH-CTP: A long-acting human growth hormone (somatrogon) under development for growth hormone deficiency. This is still in the development phase and has not been approved. Competitors are Novo Nordisk (Sogroya), Pfizer (Genotropin).
Market Dynamics
Industry Overview
The healthcare industry is characterized by technological advancements, increasing regulatory scrutiny, and evolving patient needs. The pharmaceutical market is driven by innovation and patent protection. The diagnostics market is growing due to increased demand for personalized medicine and preventative care.
Positioning
Opko occupies a niche position with its focus on specialized pharmaceuticals, diagnostics, and biologics. Its competitive advantage lies in its diversified portfolio and innovative pipeline.
Total Addressable Market (TAM)
The total addressable market for Opko's segments spans billions of dollars, covering diagnostic services, endocrinology treatments, and specialized pharmaceuticals. Opko targets specific segments within these large markets with its pipeline and products.
Upturn SWOT Analysis
Strengths
- Diversified portfolio (pharmaceuticals, diagnostics, biologics)
- Innovative pipeline (hGH-CTP)
- Established diagnostic network (BioReference Laboratories)
- Experienced leadership (Dr. Phillip Frost)
Weaknesses
- Dependence on key products (Rayaldee)
- Regulatory risks associated with drug development
- High operating expenses
- Inconsistent profitability
Opportunities
- Expansion of diagnostic services
- Commercialization of hGH-CTP and other pipeline assets
- Strategic partnerships and acquisitions
- Growth in personalized medicine
Threats
- Competition from larger pharmaceutical and diagnostic companies
- Pricing pressures and reimbursement challenges
- Patent expirations
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- Quest Diagnostics (DGX)
- Laboratory Corporation of America (LH)
- Amgen (AMGN)
- Novo Nordisk (NVO)
- Pfizer (PFE)
Competitive Landscape
Opko faces stiff competition from larger, more established players in the pharmaceutical and diagnostics industries. Its competitive advantages lie in its niche focus and innovative pipeline, but it faces challenges in terms of scale and resources.
Major Acquisitions
BioReference Laboratories
- Year: 2010
- Acquisition Price (USD millions): 1470
- Strategic Rationale: Expanded Opko's presence in the diagnostics market.
Growth Trajectory and Initiatives
Historical Growth: Opko has experienced fluctuating revenue growth driven by acquisitions and product launches. Profitability has been inconsistent.
Future Projections: Analyst estimates vary, but generally project revenue growth driven by pipeline commercialization and expansion of diagnostic services.
Recent Initiatives: Focus on advancing the hGH-CTP program, expanding diagnostic testing capabilities, and optimizing operational efficiency.
Summary
Opko Health is a diversified healthcare company with diagnostic and pharmaceutical operations but has not shown consistent profits. Its success hinges on the commercialization of hGH-CTP and the growth of BioReference Laboratories. Key watchpoints include regulatory approvals, competitive pressures, and overall profitability. The inconsistent financial performance and reliance on future pipeline success make it a speculative investment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Relations
- Analyst Reports
- Market Research Reports
- Publicly Available Information
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data and analyst estimates are subject to change. Investment decisions should be based on individual due diligence and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Opko Health Inc
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 1995-11-02 | Chairman & CEO Dr. Phillip Frost Ph.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 2997 | Website https://www.opko.com |
Full time employees 2997 | Website https://www.opko.com | ||
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offer laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, immunology, and infectious diseases; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins or peptides; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products for a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. OPKO Health, Inc. was founded in 2007 and is headquartered in Miami, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.